These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 3297965)
1. Inappropriate secretion of thyrotropin by the pituitary. Faglia G; Beck-Peccoz P; Piscitelli G; Medri G Horm Res; 1987; 26(1-4):79-99. PubMed ID: 3297965 [TBL] [Abstract][Full Text] [Related]
2. Treatment of hyperthyroidism due to inappropriate secretion of thyrotropin with the somatostatin analog SMS 201-995. Beck-Peccoz P; Mariotti S; Guillausseau PJ; Medri G; Piscitelli G; Bertoli A; Barbarino A; Rondena M; Chanson P; Pinchera A J Clin Endocrinol Metab; 1989 Jan; 68(1):208-14. PubMed ID: 2491862 [TBL] [Abstract][Full Text] [Related]
3. Sex hormone-binding globulin measurement in patients with inappropriate secretion of thyrotropin (IST): evidence against selective pituitary thyroid hormone resistance in nonneoplastic IST. Beck-Peccoz P; Roncoroni R; Mariotti S; Medri G; Marcocci C; Brabant G; Forloni F; Pinchera A; Faglia G J Clin Endocrinol Metab; 1990 Jul; 71(1):19-25. PubMed ID: 2370293 [TBL] [Abstract][Full Text] [Related]
4. Treatment of inappropriate secretion of thyrotropin with somatostatin analog SMS 201-995. Beck-Peccoz P; Medri G; Piscitelli G; Mariotti S; Bertoli A; Barbarino A; Rondena M; Martino E; Pinchera A; Faglia G Horm Res; 1988; 29(2-3):121-3. PubMed ID: 2900192 [TBL] [Abstract][Full Text] [Related]
5. Thyrotropin-induced hyperthyroidism caused by selective pituitary resistance to thyroid hormone. A new syndrome of "inappropriate secretion of TSH". Gershengorn MC; Weintraub BD J Clin Invest; 1975 Sep; 56(3):633-42. PubMed ID: 1159077 [TBL] [Abstract][Full Text] [Related]
6. Hyperthyroidism due to non-tumoural inappropriate TSH secretion. Effect of a long-acting somatostatin analogue (SMS 201-995). Williams G; Kraenzlin M; Sandler L; Burrin J; Law A; Bloom S; Joplin GF Acta Endocrinol (Copenh); 1986 Sep; 113(1):42-6. PubMed ID: 2876571 [TBL] [Abstract][Full Text] [Related]
7. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. Losa M; Giovanelli M; Persani L; Mortini P; Faglia G; Beck-Peccoz P J Clin Endocrinol Metab; 1996 Aug; 81(8):3084-90. PubMed ID: 8768879 [TBL] [Abstract][Full Text] [Related]
14. 3,5,3'-triiodothyroacetic acid therapy for thyroid hormone resistance. Kunitake JM; Hartman N; Henson LC; Lieberman J; Williams DE; Wong M; Hershman JM J Clin Endocrinol Metab; 1989 Aug; 69(2):461-6. PubMed ID: 2753985 [TBL] [Abstract][Full Text] [Related]
15. [Hyperthyroidism caused by a TSH producing pituitary adenoma]. Prasch F; Knosp SE; Steinbach R; Wogritsch S; Hurtl I; Greifeneder M; Holm C; Najemnik C; Dudczak R Acta Med Austriaca; 1999; 26(1):32-6. PubMed ID: 10230475 [TBL] [Abstract][Full Text] [Related]
16. Clinical characteristics of patients with thyrotropin-secreting pituitary adenoma. Wu YY; Chang HY; Lin JD; Chen KW; Huang YY; Jung SM J Formos Med Assoc; 2003 Mar; 102(3):164-71. PubMed ID: 12783133 [TBL] [Abstract][Full Text] [Related]
17. Endocrine, biochemical, and morphological studies of a pituitary adenoma secreting growth hormone, thyrotropin (TSH), and alpha-subunit: evidence for secretion of TSH with increased bioactivity. Beck-Peccoz P; Piscitelli G; Amr S; Ballabio M; Bassetti M; Giannattasio G; Spada A; Nissim M; Weintraub BD; Faglia G J Clin Endocrinol Metab; 1986 Apr; 62(4):704-11. PubMed ID: 2419356 [TBL] [Abstract][Full Text] [Related]